Overview
HUMA market data
Price History
HUMA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.26 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,494.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.55 – $2.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $148.3M · P/B 59.62 · P/S 86.47.
Company News
Humacyte shares are trading lower after Benchmark lowered its price target on the stock from $2 to $1.Benzinga · Aug 13, 2026, 5:40 PM
Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1Benzinga · Aug 13, 2026, 1:26 PM
Humacyte shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 12, 2026, 4:30 PM
Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M EstimateBenzinga · Aug 12, 2026, 11:01 AM
BTIG Reiterates Buy on Humacyte, Maintains $2 Price TargetBenzinga · Jul 28, 2026, 4:53 PM
Humacyte's CTEV For Coronary Artery Bypass Grafting Accepted For Investigational New Drug Status For First-In-Human Trial By FDABenzinga · Jul 27, 2026, 12:06 PM
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis AccessGlobenewswire Inc · Jul 14, 2026, 12:15 PM
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25Benzinga · Jun 17, 2026, 2:05 PM
Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual MeetingBenzinga · Jun 15, 2026, 12:15 PM
HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4Benzinga · Jun 11, 2026, 3:43 PM